TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets as of December 31, 2017 and 2016 and the movements for the periods then ended are as follows:

						Distributor &
		Patents &				Customer
		Trademarks				Relationships				Totals
*Cost or Deemed Cost*
At December 31, 2015		$	2,626,996			$	1,270,639			$	3,897,635
Additions			-				-				-
Disposals			-				-				-
At December 31, 2016		$	2,626,996			$	1,270,639			$	3,897,635

*Accumulated Amortization*
At December 31, 2015		$	1,154,113			$	1,270,639			$	2,424,752
Amortization Charge			171,108				-				171,108
Disposals			-				-				-
At December 31, 2016		$	1,325,221			$	1,270,639			$	2,595,860

*Net Book Value*
At December 31, 2015		$	1,472,883			$	-			$	1,472,883
At December 31, 2016		$	1,301,775			$	-			$	1,301,775

*Cost or Deemed Cost*
At December 31, 2016		$	2,626,996			$	1,270,639			$	3,897,635
Additions			-				-				-
Disposals			-				-				-
At December 31, 2017		$	2,626,996			$	1,270,639			$	3,897,635

*Accumulated Amortization*
At December 31, 2016		$	1,325,221			$	1,270,639			$	2,595,860
Amortization Charge			171,108				-				171,108
Disposals			-				-				-
At December 31, 2017		$	1,496,329			$	1,270,639			$	2,766,968

*Net Book Value*
At December 31, 2016		$	1,301,775			$	-			$	1,301,775
At December 31, 2017		$	1,130,667			$	-			$	1,130,667

Schedule of Estimated Aggregate Amortization Expense of Fiscal Years

The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Period		Amount
2018		$	171,108
2019			171,108
2020			171,108
2021			171,108
2022			171,108